Tuberculosis regimen change in high-burden countries

International Journal of Tuberculosis and Lung Disease

Volumn 14, Issue 12, 2010, Pages 1538-1547

  Wells, Williams A ^a   Konduri, N ^b   Chen, C ^a,c   Lee, D ^c   Ignatius, H R ^a   Gardiner, E ^a   Schwalbe, N R ^a,d  

^a GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT   (United States)

^b MANAGEMENT SCIENCES FOR HEALTH   (United States)

^c RESULTS Educational Fund   (United States)

^d GAVI Alliance   (Switzerland)

Author keywords

Highburden countries; Regimen change; Tuberculosis drugs

Indexed keywords

ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ARTICLE; DECISION MAKING; DRUG DOSE REGIMEN; HEALTH CARE PLANNING; HEALTH CARE POLICY; PRIORITY JOURNAL; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ANTITUBERCULAR AGENTS; DATA COLLECTION; DECISION MAKING; HUMANS; PATIENT PARTICIPATION; RESEARCH DESIGN; TIME FACTORS; TUBERCULOSIS;

EID: 78649382974     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Stop TB Partnership and World Health Organization. Global plan to stop TB 2006-2015. WHO/HTM/STB/2006.35. Geneva, Switzerland: WHO, 2006.
2. Spigelman M K. New tuberculosis therapeutics: a growing pipeline. J Infect Dis 2007; 196 (Suppl 1): S28-S34.
3. Stop TB Partnership / World Health Organization. New technologies for tuberculosis control: a framework for adoption, introduction and implementation. WHO/HTM/STB/2007. 40. Geneva, Switzerland: WHO, 2007.
4. Fox W, Ellard G A, Mitchison D A. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3 (Suppl 2): S231-S279.
5. World Health Organization. Treatment of tuberculosis. Guidelines for national programmes. WHO/TB/97.220. Geneva, Switzerland: WHO, 1997.
6. Arnadottir T. The Styblo model 20 years later: what holds true? Int J Tuberc Lung Dis 2009; 13: 672-690.
7. World Health Organization. Treatment of tuberculosis. Guidelines for national programmes. WHO/CDS/TB/2003.313. Geneva, Switzerland: WHO, 2003.
8. World Health Organization. Treatment of tuberculosis: guidelines. 4th ed. WHO/HTM/TB/2009.420. Geneva, Switzerland: WHO, 2009.
9. Jindani A, Nunn A J, Enarson D A. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 2004; 364: 1244-1251.
10. Moulding T, Dutt A K, Reichman L B. Fixed-dose combinations of antituberculous medications to prevent drug resistance. Ann Intern Med 1995; 122: 951-954.
11. Blomberg B, Spinaci S, Fourie B, Laing R. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. Bull World Health Organ 2001; 79: 61-68.
12. Chaulet P. Implementation of fixed-dose combinations in t uberculosis control: outline of responsibilities. Int J Tuberc Lung Dis 1999; 3 (Suppl 3): S353-S357; discussion S81-S87.
13. World Health Organization. Fixed-dose combinations for HIV/AIDS, tuberculosis and malaria. Report of a meeting held 16-18 December 2003. Geneva, Switzerland: WHO, 2003.
14. Connor J, Rafter N, Rodgers A. Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review. Bull World Health Organ 2004; 82: 935-939.
15. Bartacek A, Schutt D, Panosch B, Borek M. Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis. Int J Tuberc Lung Dis 2009; 13: 760-766.
16. The promise and reality of fixed-dose combinations with rifampicin. A joint statement of the International Union Against Tuberculosis and Lung Disease and the Tuberculosis Programme of the World Health Organization. Tubercle Lung Dis 1994; 75: 180-181.
17. Ginsberg A M. Emerging drugs for active tuberculosis. Semin Respir Crit Care Med 2008; 29: 552-559.
18. McCannon C J, Berwick D M, Massoud M R. The science of large-scale change in global health. JAMA 2007; 298: 1937-1939.
19. Frost L J, Reich M R. Access: how do good health technologies get to poor people in poor countries? Cambridge, MA, USA: Harvard Center for Population and Development Studies, 2008.
20. Williams H A, Durrheim D, Shretta R. The process of changing national malaria treatment policy: lessons from country-level studies. Health Policy Plan 2004; 19: 356-370.
21. Global Alliance for TB Drug Development. New TB regimens: what countries want. The value proposition of existing and new first-line regimens for drug-susceptible tuberculosis. New York, NY, USA: Global Alliance for TB Drug Development, 2009.
22. Blanc L. DOTS Expansion Working Group progress report 2009. DOTS Expansion Working Group meeting on improved case detection. Geneva, Switzerland: WHO, 2009. http://www. stoptb.org/wg/dots-expansion/assets/documents/CD2009/ Presentations%20Day%201/Activities-WGs-2009%20Dr% 20L.Blanc.ppt Accessed November 2009.
23. Suryanto A A, van den Broek J, Hatta M, de Soldenhoff R, van der Werf M J. Is there an increased risk of TB relapse in patients treated with fixed-dose combination drugs in Indonesia? Int J Tuberc Lung Dis 2008; 12: 174-179.
24. Rieder H L, Arnadottir T, Trébucq A, Enarson D A. Tuberculosis treatment: dangerous regimens? Int J Tuberc Lung Dis 2001; 5: 1-3.